Overview
Employees
11-50 employees
Headquarters
Orlando, Florida
Fibronostics is a healthcare technology company providing algorithm-based solutions in a variety of diagnostic testing areas, focusing on assessing liver disease existence/progression, but also other chronic areas such as coronary heart disease, stroke, diabetes, and obstructive sleep apnea. Fibronostics' LIVERFASt products provide early detection and monitoring for patients with NAFLD & NASH when a diagnosis is often missed due to limited screening with low-sensitivity tools. The current standard for diagnosis is risky and costly with mounting evidence calling for an efficacious and cost-effective non-invasive diagnostic tool. Fibronostics' HealthFACTR tool employes technology to predict risk, providing results for risks of coronary heart disease, stroke, diabetes and fatty liver disease. HealthFACTR enables action-oriented recommendations which allow healthcare professions to determine patients' risk levels and drive better patient care. Fibronostics US, Inc. operates as a diagnostic company. The Company offers non-invasive, algorithmic diagnostics, and insights to detect and manage organ lesions caused by metabolic diseases. Fibronostics US serves clients worldwide.
